← SynDRA
LEVOBETAXOLOL
SynDRA canonical compound SYN0023510 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | ADRB1 | ADRB2 |
|---|
| Mechanism of action | adrenergic receptor antagonist |
|---|
| Indication | glaucoma | intraocular pressure |
|---|
| Disease area | ophthalmology |
|---|
All known targets
Mechanisms of action (all sources)
- ADRB1 ANTAGONIST
- Beta-1 adrenergic receptor antagonist
- adrenergic receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- ADORA3
- SLC6A4
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KDR
- KCNH2
- HTR2B
- HTR1A
- HRH3
- F2
- ESR1
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- BETAXON
- levobetaxolol hydrochloride
- (-)-Betaxolol
- betaxon
- levobetaxolol HCl
- Betaxolol, (s)-
- Levobetaxolol [INN]
- Betaxon (TN)
- (S)-(-)-Betaxolol
- (S)-Betaxolol
- levobetaxololum
- CHEBI:59254
- RefChem:153195
- DTXCID50161832
- (S)-Betaxolol hydrochloride;AL-1577A
- UNII-75O9XHA4TU
- SCHEMBL23532
- LEVOBETAXOLOL [WHO-DD]
- GTPL8035
- orb1706016
- BDBM25752
- EBC-26564
- STK636241
- AKOS005568173
- NCGC00386278-01
- AC-30590
- HY-121166
- NS00098733
- T19682
- AB01566926_01
- Betaxolol Impurity 6; Levobetaxolol Hydrochloride
- EN300-18563034
- BRD-K43883465-003-01-5
- (S)-betaxolol
- (-)-betaxolol
- AL-1577A
- Betaxon®
- ليفوبيتاكسولول
Look up LEVOBETAXOLOL in the interactive SynDRA portal →